MX2022010564A - Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque. - Google Patents
Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque.Info
- Publication number
- MX2022010564A MX2022010564A MX2022010564A MX2022010564A MX2022010564A MX 2022010564 A MX2022010564 A MX 2022010564A MX 2022010564 A MX2022010564 A MX 2022010564A MX 2022010564 A MX2022010564 A MX 2022010564A MX 2022010564 A MX2022010564 A MX 2022010564A
- Authority
- MX
- Mexico
- Prior art keywords
- therapy
- patients
- adrenomedullin
- adm
- shock
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000035939 shock Effects 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La materia objeto de la presente invención es un anticuerpo anti-adrenomedulina (ADM) o un fragmento de anticuerpo anti-adremedulina o un andamiaje no Ig anti-ADM para usarse en terapia de pacientes en choque y/o para usarse en terapia de enfermedades que necesitan admisión de los pacientes a la unidad de terapia intensiva (ICU).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20159913 | 2020-02-27 | ||
EP20206317 | 2020-11-06 | ||
PCT/EP2021/055068 WO2021170880A2 (en) | 2020-02-27 | 2021-03-01 | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010564A true MX2022010564A (es) | 2022-11-30 |
Family
ID=74732950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010564A MX2022010564A (es) | 2020-02-27 | 2021-03-01 | Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230250166A1 (es) |
EP (1) | EP4110812A2 (es) |
JP (1) | JP2023515985A (es) |
KR (1) | KR20220145898A (es) |
CN (1) | CN115244081A (es) |
AU (1) | AU2021227279A1 (es) |
BR (1) | BR112022016843A2 (es) |
CA (1) | CA3169447A1 (es) |
IL (1) | IL295951A (es) |
MX (1) | MX2022010564A (es) |
WO (1) | WO2021170880A2 (es) |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
US6864237B2 (en) * | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
EP1800131A2 (en) | 2004-09-09 | 2007-06-27 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
US8748351B2 (en) | 2009-12-14 | 2014-06-10 | Scil Proteins Gmbh | Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
ES2729652T3 (es) | 2010-06-08 | 2019-11-05 | Pieris Pharmaceuticals Gmbh | Muteína de lipocalina lacrimal unidas a IL-4R alpha |
WO2013072513A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
SG11201402354YA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
AU2012338730B2 (en) * | 2011-11-16 | 2017-07-06 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
US20140328853A1 (en) | 2011-11-16 | 2014-11-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
DK2594588T3 (da) | 2011-11-16 | 2014-07-21 | Adrenomed Ag | Anti-Adrenomedullin (ADM)-antistof eller anti-ADM-antistoffragment eller anti-ADM-ikke-Ig-protein-scaffold til anvendelse i terapi |
US20190145981A1 (en) * | 2016-04-21 | 2019-05-16 | Sphingotec Therapeutics Gmbh | Methods for determining dpp3 and therapeutic methods |
-
2021
- 2021-03-01 CA CA3169447A patent/CA3169447A1/en active Pending
- 2021-03-01 EP EP21708010.0A patent/EP4110812A2/en active Pending
- 2021-03-01 AU AU2021227279A patent/AU2021227279A1/en active Pending
- 2021-03-01 CN CN202180016775.6A patent/CN115244081A/zh active Pending
- 2021-03-01 MX MX2022010564A patent/MX2022010564A/es unknown
- 2021-03-01 JP JP2022551701A patent/JP2023515985A/ja active Pending
- 2021-03-01 WO PCT/EP2021/055068 patent/WO2021170880A2/en unknown
- 2021-03-01 BR BR112022016843A patent/BR112022016843A2/pt unknown
- 2021-03-01 KR KR1020227033527A patent/KR20220145898A/ko unknown
- 2021-03-01 US US17/802,817 patent/US20230250166A1/en active Pending
- 2021-03-01 IL IL295951A patent/IL295951A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220145898A (ko) | 2022-10-31 |
EP4110812A2 (en) | 2023-01-04 |
CA3169447A1 (en) | 2021-09-02 |
US20230250166A1 (en) | 2023-08-10 |
JP2023515985A (ja) | 2023-04-17 |
WO2021170880A3 (en) | 2021-10-28 |
BR112022016843A2 (pt) | 2022-10-11 |
WO2021170880A2 (en) | 2021-09-02 |
CN115244081A (zh) | 2022-10-25 |
AU2021227279A1 (en) | 2022-10-20 |
IL295951A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
NO20056236L (no) | Behandling med anti-VEGF-antistoffer | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
NO20083697L (no) | Fremgangsmater for anvendelse av antistoffer mot human IL-22 | |
NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
EA202190749A1 (ru) | Способы комбинированной терапии | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
EA202191736A1 (ru) | Комбинированная терапия hbv | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
EA202092518A1 (ru) | Композиции и способы лечения рака | |
IL285267A (en) | Antibodies associated with an infected form of calreticulin mutation and preventive diagnostics, or treatment factor for neoplasmic myeloproliferative | |
MX2021003119A (es) | Anticuerpos anti-klrg1. | |
MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
CL2023000099A1 (es) | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular | |
MX2019007107A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. | |
MX2019002382A (es) | Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar. | |
NO20093536L (no) | Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. |